Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: BI 135585 XX

Study type: Interventional

Funder types: Industry

Identifiers

NCT01652742

1283.34

2012-000844-85 (EudraCT Number)

Details and patient eligibility

About

To investigate the pharmacokinetics and pharmacodynamics of BI 135585 XX following single dose administration.

Enrollment: 9 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Healthy male subjects
2. overweight or obese

Exclusion criteria

1. Any relevant deviation from healthy conditions

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

9 participants in 1 patient group

BI 135585 XX

Experimental group

Description:

one single dose

Treatment:

Drug: BI 135585 XX